Showing results (11-20 of 15) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Pharmacology and Therapeutics|March 16, 2007
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyN A Farid, C D Payne, D S Small, et al.Current Medical Research and Opinion|June 18, 2009
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjectsN A Farid, J A Jakubowski, C D Payne, et al.Journal of Thrombosis and Haemostasis : JTH|November 21, 2007
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activitiesA L Frelinger, J A Jakubowski, Y Li, et al.Journal of Clinical Pharmacy and Therapeutics|September 12, 2009
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal diseaseD S Small, R E Wrishko, C S Ernest, et al.Thrombosis and Haemostasis|July 11, 2014
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseP A Gurbel, T O Bergmeijer, U S Tantry, et al.Pageof 2